[{"orgOrder":0,"company":"Egis Pharmaceuticals PLC","sponsor":"Crescita Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2021","type":"Licensing Agreement","leadProduct":"Lidocaine","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Egis Pharmaceuticals PLC","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Egis Pharmaceuticals PLC \/ Egis Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Egis Pharmaceuticals PLC \/ Egis Pharmaceuticals"},{"orgOrder":0,"company":"Egis Pharmaceuticals PLC","sponsor":"National Institute of Pharmacy and Nutrition","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Favipiravir","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Egis Pharmaceuticals PLC","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Egis Pharmaceuticals PLC \/ National Institute of Pharmacy and Nutrition","highestDevelopmentStatusID":"12","companyTruncated":"Egis Pharmaceuticals PLC \/ National Institute of Pharmacy and Nutrition"}]

Find Clinical Drug Pipeline Developments & Deals by Egis Pharmaceuticals PLC

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Lead Product(s) : Lidocaine,Tetracaine

                          Therapeutic Area : Neurology

                          Study Phase : Approved

                          Recipient : Crescita Therapeutics

                          Deal Size : Undisclosed

                          Deal Type : Licensing Agreement

                          Details : The formulation contains a eutectic mixture of 7% lidocaine and 7% tetracaine that utilizes phase-changing topical cream Peel technology. In clinical studies, the mean duration of anesthesia has been shown to be in the range of 7 to 9 hours after the app...

                          Brand Name : Pliaglis

                          Molecule Type : Small molecule

                          Upfront Cash : $0.7 million

                          December 13, 2021

                          Lead Product(s) : Lidocaine,Tetracaine

                          Therapeutic Area : Neurology

                          Highest Development Status : Approved

                          Recipient : Crescita Therapeutics

                          Deal Size : Undisclosed

                          Deal Type : Licensing Agreement

                          Egis Pharmaceuticals

                          02

                          Lead Product(s) : Favipiravir

                          Therapeutic Area : Infections and Infectious Diseases

                          Study Phase : Approved

                          Sponsor : National Institute of Pharmacy and Nutrition

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          Details : The active ingredient favipiravir manufactured by Hungarian pharmaceutical company Egis has been licenced for treatment of Covid-19 by the National Institute of Pharmacy and Nutrition (OGYÉI).

                          Brand Name : Favipiravir-Generic

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          December 20, 2020

                          Lead Product(s) : Favipiravir

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Approved

                          Sponsor : National Institute of Pharmacy and Nutrition

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          Egis Pharmaceuticals